Effect of Real Time Continuous Glucose Monitoring System on the Management of Type 2 Diabetes
1 other identifier
interventional
127
1 country
1
Brief Summary
The purpose of this study is to determine whether the Guardian Continuous Glucose Monitoring System in the home setting is more useful than frequent self blood glucose monitoring with a view to modifying patient's diet and exercise habits or improvement self disease control efforts and at last glycemic control in patients with type 2 diabetes
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable type-2-diabetes
Started Feb 2007
Shorter than P25 for not_applicable type-2-diabetes
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2007
CompletedFirst Submitted
Initial submission to the registry
September 27, 2007
CompletedFirst Posted
Study publicly available on registry
September 28, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2007
CompletedMay 20, 2008
May 1, 2008
8 months
September 27, 2007
May 19, 2008
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
HbA1c, fasting blood glucose level, weight change, blood pressure in the morning, lipid profiles
basline, 12weeks later
Secondary Outcomes (1)
three day diary meals and seven day physical activity diary
basline, 12 weeks later
Study Arms (2)
A
EXPERIMENTALGuardina RT monitoring
B
ACTIVE COMPARATORInterventions
Eligibility Criteria
You may qualify if:
- Type 2 diabetes
- Group 1: HbA1c \< 8% with a stable insulin or oral hypoglycemic agents (OHA) regimen for the prior 2 months with no plans to switch modality of insulin or OHA administration during the next 3months.
- Group 2: HbA1c \>= 8% and the fasting blood glucose must be \< 130 at the same time with a stable insulin or oral hypoglycemic agents (OHA) regimen for the prior 2 months with no plans to switch modality of insulin or OHA administration during the next 3months
You may not qualify if:
- Use of corticosteroids or hormone therapy within the last 6 months
- Presence of another chronic illness
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Korea Universitylead
Study Sites (1)
Division of Endocrinology and Metabolism, Department of Internal Medicine,Korea University College of Medicine
Seoul, 152-703, South Korea
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sei H Baik, MD
Division of Endocrinology and Metabolism, Department of Internal Medicine,Korea University College of Medicine
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
September 27, 2007
First Posted
September 28, 2007
Study Start
February 1, 2007
Primary Completion
October 1, 2007
Study Completion
October 1, 2007
Last Updated
May 20, 2008
Record last verified: 2008-05